Log in to search using one of your social media accounts:

 

Cerenovus receives fda clearance for next generation stent retriever device used to treat ischemic stroke
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces European Commission Approval of JULUCA ®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 19, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 17, 2018 Category: Pharmaceuticals Source Type: news

Biosense webster, inc launches sheath designed to reduce radiation exposure and improve ablation procedure efficiency
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 9, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces DARZALEX ® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 8, 2018 Category: Pharmaceuticals Source Type: news

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 5, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 UBS Global Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present Data in Treatment-Resistant Depression, Schizophrenia, Health Economics and Outcomes and Population Health at American Psychiatric Association 2018 Meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Biosense webster, inc. launches study to evaluate novel high power, short duration modality for treatment of atrial fibrillation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 3, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Consumer and Medical Devices Business Review
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 2, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 2, 2018 Category: Pharmaceuticals Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT ® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 30, 2018 Category: Pharmaceuticals Source Type: news

Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Dividend Increase of 7.1%
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 26, 2018 Category: Pharmaceuticals Source Type: news

New PROTI 360 ° Family of Implants from DePuy Synthes Is Designed to Enhance Spinal Fusion Surgery Outcomes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 26, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 25, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2018 First-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 17, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 17, 2018 Category: Pharmaceuticals Source Type: news

Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 16, 2018 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 12, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS ® with Transitions® Light Intelligent Technology™
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 11, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Institute Adds Innovative Analytics-Based Learning Platform to Help Surgeons Improve Technical Skills and Clinical Outcomes Across a Range of Specialties
Use of digital technology and analytics will reinvent professional education (Source: Johnson and Johnson)
Source: Johnson and Johnson - April 7, 2018 Category: Pharmaceuticals Source Type: news

Ethicon Highlights New Capabilities to Reduce Exposure to Surgical Smoke at the Association of PeriOperative Nurses (AORN) Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 27, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces Positive CHMP Opinion for JULUCATM ▼ (dolutegravir/rilpivirine)
If approved, stable, virologically suppressed adults living with HIV-1 could have the option to switch to a single-pill, two-drug regimen (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 23, 2018 Category: Pharmaceuticals Source Type: news

Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson
Joseph Wolk Promoted to Executive Vice President, Chief Financial Officer (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 20, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 20, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 16, 2018 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 15, 2018 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2018 Category: Pharmaceuticals Source Type: news

New Late-Breaking Study Finds Wearable Electrocardiogram (ECG) Monitoring Patch Can Detect Atrial Fibrillation Earlier and More Efficiently than Routine Care
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 10, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in Barclays Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 7, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Human Performance Institute Invests in the Future of Wellbeing with New $18 Million Facility in Lake Nona Medical City
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 28, 2018 Category: Pharmaceuticals Source Type: news

Acclarent receives fda clearance for expanded indication of acclarent aera  eustachian tube balloon dilation system
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 27, 2018 Category: Pharmaceuticals Source Type: news

New Late-Breaking XARELTO ® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 26, 2018 Category: Pharmaceuticals Source Type: news

New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 21, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 21, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 20, 2018 Category: Pharmaceuticals Source Type: news

New tremfya ® (guselkumab) data demonstrates long-term skin clearance in patients with moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

Johnson & johnson consumer presents new scientific research at 2018 american academy of dermatology annual meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

Plastic And Reconstructive Surgery Journal Publishes Ten-Year Clinical Study Data Highlighting Safety Of MENTOR ® MemoryShape® Gel Breast Implants
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 15, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 9, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 CAGNY Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen enters into worldwide collaboration with theravance biopharma for oral, pan-jak inhibitor drug candidate for the treatment of inflammatory bowel disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 7, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 1, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA ® (abiraterone acetate) and Erdafitinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 25, 2018 Category: Pharmaceuticals Source Type: news